Teva and Fosun Pharma Collaborate on Novel Anti-Cancer Therapy

Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical Co., Ltd. have announced a strategic partnership focused on the development of the investigational therapy TEV-56278, an anti-PD1-IL2 ATTENUKINE, for oncology. This therapy, which is currently in Phase 1, is aimed at treating various cancers including melanoma. Fosun Pharma secured exclusive rights to develop and commercialize TEV-56278 in China, Hong Kong, Macau, Taiwan, and select Southeast Asian countries, while Teva retains rights for other regions. This collaboration aims to capitalize on Fosun's oncology experience and market presence in China to advance the therapy's development. The partnership supports Teva's 'Pivot to Growth' strategy by leveraging clinical data generated in Asia for global applications, signifying a strategic move to accelerate drug development and market penetration. Both companies express optimism about the potential synergies and advancements this partnership will bring to global cancer treatment efforts.